Drug Trial Radar · NCT06786624
Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jan 22, 2025
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Jan 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Conditions
- Major Depressive Disorder
Interventions
OsavampatorDrug
Osavampator tablets
PlaceboDrug
Matching placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56Time frame: Baseline, Day 56
Locations
30 sites in 4 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Little Rock, Arkansas · Recruiting
Neurocrine Clinical Site
Garden Grove, California · Withdrawn
Neurocrine Clinical Site
Orange, California · Withdrawn
Neurocrine Clinical Site
Pico Rivera, California · Recruiting
Neurocrine Clinical Site
San Diego, California · Recruiting
Neurocrine Clinical Site
Upland, California · Withdrawn
Neurocrine Clinical Site
Hollywood, Florida · Recruiting
Neurocrine Clinical Site
Maitland, Florida · Recruiting
Neurocrine Clinical Site
Boston, Massachusetts · Recruiting
Neurocrine Clinical Site
Watertown, Massachusetts · Suspended
Neurocrine Clinical Site
Mount Kisco, New York · Recruiting
Neurocrine Clinical Site
Avon Lake, Ohio · Recruiting
Neurocrine Clinical Site
Westlake, Ohio · Withdrawn
Neurocrine Clinical Site
Dallas, Texas · Withdrawn
Neurocrine Clinical Site
Houston, Texas · Recruiting
Neurocrine Clinical Site
Richmond, Texas · Withdrawn
Neurocrine Clinical Site
The Woodlands, Texas · Suspended
Neurocrine Clinical Site
Everett, Washington · Recruiting
Neurocrine Clinical Site
Zagreb, Croatia · Active not recruiting
Neurocrine Clinical Site
Zagreb, Croatia · Active not recruiting
Neurocrine Clinical Site
Pilsen, Czechia · Active not recruiting
Neurocrine Clinical Site
Prague, Czechia · Active not recruiting
Neurocrine Clinical Site
Prague, Czechia · Active not recruiting
Neurocrine Clinical Site
Prague, Czechia · Active not recruiting
Neurocrine Clinical Site
Prague, Czechia · Active not recruiting
Neurocrine Clinical Site
Bełchatów, Poland · Active not recruiting
Neurocrine Clinical Site
Bialystok, Poland · Active not recruiting
Neurocrine Clinical Site
Gdansk, Poland · Active not recruiting
Neurocrine Clinical Site
Grudziądz, Poland · Active not recruiting
Neurocrine Clinical Site
Katowice, Poland · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.